A new way to keep dialysis access working well
Contact Pathway Inhibitor to Prevent Vascular Access Failure
This project is developing a new medication to help keep the special tubes used for kidney dialysis, called AV grafts, open and working for patients with end-stage kidney disease.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aronora, INC. NIH-funded |
| Lab location | 1 site (Portland, UNITED STATES) |
| Project ID | NIH-11121787 on NIH RePORTER |
What this research studies
For people with end-stage kidney disease who need hemodialysis, keeping their vascular access working is crucial. While AV fistulas are often preferred, many patients, especially Black/African American individuals and women, rely on AV grafts which can frequently become blocked or infected. This research focuses on creating a unique medicine, AB023, designed to prevent these grafts from clotting. By keeping the grafts open longer, patients can continue their life-saving dialysis treatments more smoothly. We've already completed an early clinical trial that suggests this new medicine is safe for patients.
Who could benefit from this research
Good fit: Ideal candidates are patients with end-stage kidney disease who use AV grafts for hemodialysis and experience issues with their grafts becoming blocked.
Not a fit: Patients who do not use AV grafts for hemodialysis or who do not have end-stage kidney disease would not directly benefit from this specific treatment.
Why it matters
Potential benefit: If successful, this new medication could significantly extend the life of AV grafts, reducing complications and improving the quality of life for dialysis patients.
How similar studies have performed: A pilot phase 2a clinical trial has already been completed, showing early indications that this approach may be safe in medically complex patients.
Where this research is happening
Portland, UNITED STATES
- Aronora, INC. — Portland, United States (Active)
Researchers
- Principal investigator: Lorentz, Christina U — Aronora, INC.
- Study coordinator: Lorentz, Christina U
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.